You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 25, 2024

lumryz Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Lumryz patents expire, and what generic alternatives are available?

Lumryz is a drug marketed by Avadel Cns and is included in one NDA. There are twenty-six patents protecting this drug.

This drug has thirty patent family members in ten countries.

The generic ingredient in LUMRYZ is sodium oxybate. There are one thousand four hundred and seventy-two drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the sodium oxybate profile page.

DrugPatentWatch® Generic Entry Outlook for Lumryz

There are two tentative approvals for the generic drug (sodium oxybate), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

< Available with Subscription >

  Subscribe

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for lumryz?
  • What are the global sales for lumryz?
  • What is Average Wholesale Price for lumryz?
Summary for lumryz
International Patents:30
US Patents:26
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 37
Patent Applications: 75
Drug Prices: Drug price information for lumryz
What excipients (inactive ingredients) are in lumryz?lumryz excipients list
DailyMed Link:lumryz at DailyMed
Drug patent expirations by year for lumryz
Drug Prices for lumryz

See drug prices for lumryz

US Patents and Regulatory Information for lumryz

lumryz is protected by twenty-six US patents and three FDA Regulatory Exclusivities.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Avadel Cns LUMRYZ sodium oxybate FOR SUSPENSION, EXTENDED RELEASE;ORAL 214755-003 May 1, 2023 RX Yes No 12,115,142 ⤷  Subscribe Y ⤷  Subscribe
Avadel Cns LUMRYZ sodium oxybate FOR SUSPENSION, EXTENDED RELEASE;ORAL 214755-004 May 1, 2023 RX Yes No 10,973,795 ⤷  Subscribe Y ⤷  Subscribe
Avadel Cns LUMRYZ sodium oxybate FOR SUSPENSION, EXTENDED RELEASE;ORAL 214755-002 May 1, 2023 RX Yes No 12,115,143 ⤷  Subscribe Y ⤷  Subscribe
Avadel Cns LUMRYZ sodium oxybate FOR SUSPENSION, EXTENDED RELEASE;ORAL 214755-002 May 1, 2023 RX Yes No 11,400,065 ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for lumryz

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
UCB Pharma Ltd Xyrem sodium oxybate EMEA/H/C/000593
Treatment of narcolepsy with cataplexy in adult patients.
Authorised no no no 2005-10-13
D&A Pharma Hopveus sodium oxybate EMEA/H/C/004962
Substitution treatment for alcohol dependence within a framework of careful medical supervision along with continuous psychosocial support and social rehabilitation. Treatment should be initiated only in patients resistant to existing interventions or in patients for whom existing therapies are contra-indicated or not recommended.
Refused no no no 2020-07-06
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for lumryz

See the table below for patents covering lumryz around the world.

Country Patent Number Title Estimated Expiration
World Intellectual Property Organization (WIPO) 2018015563 ⤷  Subscribe
Brazil 112021013766 ⤷  Subscribe
Canada 3127871 COMPOSITIONS DE GAMMA-HYDROXYBUTYRATE PRESENTANT UNE PHARMACOCINETIQUE AMELIOREE A L'ETAT ALIMENTE (GAMMA-HYDROXYBUTYRATE COMPOSITIONS HAVING IMPROVED PHARMACOKINETICS IN THE FED STATE) ⤷  Subscribe
Japan 2024069488 ⤷  Subscribe
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for lumryz

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1666481 17C1031 France ⤷  Subscribe PRODUCT NAME: TOFACITINIB,EVENTUELLEMENT SOUS LA FORME D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE,DONT LE CITRATE DE SODIUM; REGISTRATION NO/DATE: EU/1/17/1178 20170324
2932970 18C1043 France ⤷  Subscribe PRODUCT NAME: UNE COMBINAISON COMPRENANT DU DOLUTEGRAVIR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI,EN PARTICULIER LE SEL DE SODIUM DU DOLUTEGRAVIR,ET DE LA RILPIVIRINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI,EN PARTICULIER LE CHLORHYDRATE DE RILPIVIRINE; REGISTRATION NO/DATE: EU/1/18/1282 20180518
0806968 SPC/GB07/011 United Kingdom ⤷  Subscribe PRODUCT NAME: GADOFOSVESET TRISODIUM; REGISTERED: UK EU/1/05/313/001 20051003; UK EU/1/05/313/002 20051003; UK EU/1/05/313/003 20051003; UK EU/1/05/313/004 20051003; UK EU/1/05/313/005 20051003; UK EU/1/05/313/006 20051003; UK EU/1/05/313/007 20051003; UK EU/1/05/313/008 20051003; UK EU/1/05/313/009 20051003
2932970 1890039-9 Sweden ⤷  Subscribe PRODUCT NAME: DOLUTEGRAVIR SODIUM + RILPIVIRINE HYDROCHLORIDE; REG. NO/DATE: EU/1/18/1282 20180518
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Lumryz Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for LUMRYZ

Introduction

LUMRYZ, an extended-release formulation of sodium oxybate developed by Avadel Pharmaceuticals, has been making significant waves in the pharmaceutical market since its launch in June 2023. Here, we delve into the market dynamics and financial trajectory of this groundbreaking drug.

FDA Approval and Clinical Superiority

LUMRYZ received FDA approval for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients with narcolepsy, marking a significant milestone. The FDA determined that LUMRYZ, dosed once at bedtime, demonstrates clinical superiority over twice-nightly oxybate products, a finding upheld by a recent court ruling[4][5].

Market Performance

Since its launch, LUMRYZ has shown robust market penetration. Here are some key highlights:

Q2 2024 Performance

  • Net revenue from LUMRYZ sales reached $41.5 million, a substantial increase from the $1.5 million in Q2 2023.
  • The patient base expanded to over 1,900 as of June 30, 2024, up from 1,400 in March and 900 in December 2023[2].

Q3 2024 Performance

  • Avadel generated $50 million in net product revenue from LUMRYZ sales in the third quarter of 2024.
  • As of September 30, 2024, there were 2,300 patients on LUMRYZ, with 700 patients initiating therapy during the quarter[4][5].

Patient Demand and Enrollment

  • The drug has seen consistent and growing patient demand, particularly among those new to oxybate therapy. Over 3,800 patients are enrolled in support services, and 2,400 have initiated therapy since the launch[2][4].

Financial Highlights

Here are the key financial metrics that highlight the trajectory of LUMRYZ:

Revenue Growth

  • In the fourth quarter of 2023, Avadel estimated $19 million in net revenue from LUMRYZ sales, with a full-year estimate of $28 million[1].
  • Q2 2024 saw a significant jump to $41.5 million in net revenue, and Q3 2024 further increased to $50 million[2][4].

Gross Profit and Net Loss

  • In Q2 2024, the gross profit from LUMRYZ sales was $38.7 million, while the net loss was $13.8 million, an improvement from the $64.4 million loss in Q2 2023[2].
  • Despite the net loss, the company's financial performance indicates a positive trend, driven by increasing revenue and improving operational efficiencies.

Cash Position

  • As of December 31, 2023, Avadel had approximately $105 million in cash, cash equivalents, and marketable securities. By June 30, 2024, this had decreased to $71.4 million, reflecting ongoing investments in R&D and marketing efforts[1][2].

Pipeline and Future Indications

Avadel is actively expanding the potential indications for LUMRYZ:

Idiopathic Hypersomnia

  • The company has initiated a Phase 3 trial (REVITALYZ study) to evaluate the efficacy and safety of LUMRYZ in idiopathic hypersomnia, a condition characterized by excessive daytime sleepiness without cataplexy[2][4].

Pediatric Narcolepsy

  • Avadel is awaiting an FDA decision on the supplemental New Drug Application (sNDA) for LUMRYZ in pediatric narcolepsy, with a PDUFA date set for September 7, 2024. This could significantly expand the patient population for LUMRYZ[2][4].

Regulatory and Legal Wins

  • The FDA approval for pediatric use and the court ruling affirming LUMRYZ's clinical superiority over twice-nightly oxybate products have been crucial in solidifying its market position. This has also secured Orphan Drug Exclusivity through October 16, 2031[4][5].

Provider and Patient Engagement

  • Nearly 1,800 healthcare providers have completed the LUMRYZ REMS (Risk Evaluation and Mitigation Strategy) certification process, including both experienced oxybate prescribers and new providers. This widespread adoption among healthcare professionals is a testament to the drug's acceptance and efficacy[1].

Key Takeaways

  • Strong Revenue Growth: LUMRYZ has generated significant revenue, with $41.5 million in Q2 2024 and $50 million in Q3 2024.
  • Expanding Patient Base: The patient base has grown substantially, with over 2,300 patients on LUMRYZ as of September 30, 2024.
  • Regulatory and Legal Successes: FDA approval for pediatric use and a court ruling affirming clinical superiority have strengthened LUMRYZ's market position.
  • Pipeline Progress: Ongoing Phase 3 trials for idiopathic hypersomnia and an impending FDA decision on pediatric narcolepsy indicate potential future growth.

FAQs

Q: What is LUMRYZ, and what is it used for?

A: LUMRYZ is an extended-release formulation of sodium oxybate approved by the FDA for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients with narcolepsy.

Q: How has LUMRYZ performed financially since its launch?

A: LUMRYZ has shown strong financial performance, with net revenue of $41.5 million in Q2 2024 and $50 million in Q3 2024, indicating robust market penetration.

Q: What are the future indications being explored for LUMRYZ?

A: Avadel is exploring LUMRYZ for idiopathic hypersomnia through a Phase 3 trial and is awaiting an FDA decision on its use in pediatric narcolepsy.

Q: How many patients are currently using LUMRYZ?

A: As of September 30, 2024, there were 2,300 patients on LUMRYZ, with 700 patients initiating therapy during the third quarter.

Q: What regulatory and legal milestones has LUMRYZ achieved?

A: LUMRYZ has received FDA approval for pediatric use and has been upheld in court as clinically superior to twice-nightly oxybate products, securing Orphan Drug Exclusivity through 2031.

Sources

  1. Avadel Pharmaceuticals Announces Strong LUMRYZ Launch Performance and Provides Preliminary Fourth Quarter and Full Year 2023 Financial Highlights. Avadel Pharmaceuticals.
  2. Avadel Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2024 Financial Results. Stock Titan.
  3. Avadel Pharmaceuticals Announces Data Supporting Clinical Profile for LUMRYZ™ Sodium Oxybate. Nasdaq.
  4. Avadel's Narcolepsy Treatment Lumryz Brings in $50 Million in Q3. Sleep Review Magazine.
  5. Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2024 Financial Results. Avadel Pharmaceuticals.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.